Neurogene, Inc. (NGNE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$38.60+2.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NGNE
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-1.4) + peer(0.2*0.0) + term(0.0) → -0.49% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition On August 11, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition On May 12, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on May 12, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The…
Results of Operations and Financial Condition On March 24, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on March 24, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report o…
Results of Operations and Financial Condition On November 13, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on November 13, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on…
Results of Operations and Financial Condition On August 11, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.…
and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
Results of Operations and Financial Condition On March 24, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2024. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on March 24, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report o…
and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
Results of Operations and Financial Condition On August 9, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2024. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 9, 2024, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. T…
Results of Operations and Financial Condition On May 10, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2024. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on May 10, 2024, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The…
Results of Operations and Financial Condition On March 18, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2023. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this